ARS Pharmaceuticals, Inc.
Regulated industryPhysical productsDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $3.65
- 52-Week Range
- $2.44 – $13.15
- Market Cap
- $370.95M
- P/E (TTM)
- —
- EPS (TTM)
- -2.01
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- —
- PEG Ratio
- —
- Return on Equity
- -294.57%
- Return on Assets
- -39.49%
- Gross Margin
- 45.86%
- Operating Margin
- -161.50%
- Profit Margin
- -163.64%
- Current Ratio
- 3.25
- Debt/Equity
- —
- Total Debt
- $197.02M
- Free Cash Flow
- $-101.63M
- Revenue Growth
- 16.00%
- Earnings Growth
- —
- Enterprise Value
- $429.61M
Market Snapshot
About
ARS Pharmaceuticals is a biopharmaceutical company developing treatments for severe allergic reactions. The company is advancing neffy, an investigational needle-free nasal epinephrine spray designed as an alternative to auto-injectors for the emergency treatment of Type I allergic reactions including anaphylaxis.